Drug Topics

JUNE 3, 2025

A conversation with Erin Albert, MBA, PharmD, JD, DASPL, chief of pharmacy relations, network and privacy, at Cost Plus Drugs.

Independent Pharmacies 467

Independent Pharmacies 467

PharmaVoice

JUNE 3, 2025

Drugmakers like J&J and Astellas are looking beyond today’s cancer treatments for the windows of opportunity decades down the road.

130

130

Drug Topics

JUNE 3, 2025

Social determinants of health have significant impacts on health and quality of life, but little is known about the impact during menopause.

343

343

Pharmacy Times

JUNE 3, 2025

Amanda Gronniger, PharmD, CPh, BCCP discusses practical strategies pharmacists can use to improve cholesterol management, from lifestyle counseling to emerging therapies.

123

123

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

JUNE 3, 2025

Esaxerenone is a nonsteroidal mineralocorticoid receptor blocker that is being studied for its effectiveness for diabetes-associated mineralocorticoid receptor-related hypertension.

343

343

The Checkup by Singlecare

JUNE 3, 2025

Growing up, there is a strong emphasis on drinking milk to fulfill your vitamin D and calcium needs. But as adults, it’s easy to forget you still need these essential nutrients. While some people eat enough as part of a balanced diet, others develop low calcium levels (calcium deficiency) and may need a prescription supplement like calcitriol , which is sold under the brand name Rocaltrol.

Labelling 97

Labelling FDA 97

STAT

JUNE 3, 2025

Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are wafting across the Pharmalot campus, where the official mascots are foraging for their breakfast and rousing the neighbors. This means we are free to focus on the matters at hand — rummaging through our to-do list and making cups of stimulation. Our choice today is banana split, which is fast becoming a trusty favorite.

FDA 95

FDA Labelling 95

PharmaVoice

JUNE 3, 2025

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.

130

130

STAT

JUNE 3, 2025

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds.  Sign up here. Good morning! It’s June 3 — a significant day in the fictional “Gilmore Girls” town of Stars Hollow, and just another day of June/late spring/Pride for those of us in the real world. But there’s plenty of news today, so let’s get into it.

94

94

Pharmacy Times

JUNE 3, 2025

The FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer after positive results in the ARANOTE clinical trial.

FDA 73

FDA 73

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

JUNE 3, 2025

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Morning! Today, STAT’s Matthew Herper chats with J&J’s R&D chief, we see the radiopharmaceutical Pluvicto being considered earlier for prostate cancer, and more.

75

75

Pharmacy Times

JUNE 3, 2025

The 2025 ASCO Annual Meeting discusses the latest advancements in understanding and treating precursor diseases.

73

73

STAT

JUNE 3, 2025

Y ou’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences.  Sign up to get it  delivered in your inbox every Tuesday and Thursday. Good morning health tech readers!

73

73

Pharmacy Times

JUNE 3, 2025

Chip Hailey, a 74-year-old pharmacist with hemophilia B, shares how gene therapy has liberated him from decades of challenging treatment and restored his independence.

125

125

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Fierce Healthcare

JUNE 3, 2025

CMS plans to launch a national provider directory, a federated identity verification system and digital insurance cards.

Insurance 94

Insurance 94

Pharmacy Times

JUNE 3, 2025

Panelists discuss how ongoing monitoring and individualized treatment adjustments can help mitigate adverse events associated with low-density lipoprotein cholesterol (LDL-C)lowering therapies while maintaining efficacy and explore strategies to navigate insurance barriers and ensure timely access to nonstatin LDL-Clowering medications.

Insurance 65

Insurance 65

The FDA Law Blog

JUNE 3, 2025

By Larry K. Houck We appreciate receiving feedback on our blog posts. We received a response to our post on the prescribing red flags indicating the likelihood of certain prescriptions filled by Walgreens pharmacies were invalid because they lacked a legitimate medical purpose or were not issued in the usual course of professional practice. Press Release, Walgreens Agrees To Pay Up to $350M for Illegally Filling Unlawful Opioid Prescriptions and Submitting False Claims, U.S.

Prescription Filling 59

Prescription Filling Controlled Substances 59

Pharmacy Times

JUNE 3, 2025

Experts share insights on patient discussions and side effect management strategies in HER2 breast cancer.

65

65

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmaceutical Technology

JUNE 3, 2025

First-in-human data for the trispecific antibody suggest a paradigm shift for the relapsed/refractory multiple myeloma space.

52

52

Pharmacy Times

JUNE 3, 2025

Panelists discuss how key clinical and economic factors, such as efficacy, safety, cost-effectiveness, patient adherence, and proper monitoring, should be considered when evaluating new low-density lipoprotein cholesterol (LDL-C)lowering medications for formulary inclusion, and how health care teams can optimize therapy management through patient counseling, monitoring, and coordination of injection therapies to improve outcomes.

65

65

pharmaphorum

JUNE 3, 2025

The FDA has rolled out its highly-touted generative AI tool, almost a month early, with a promise to reduce the time taken for regulatory reviews

FDA 89

FDA 89

Pharmacy Times

JUNE 3, 2025

Explore the latest advancements in myelofibrosis treatment, focusing on JAK inhibitors and pegylated interferons for improved patient outcomes.

65

65

DiversifyRx

JUNE 3, 2025

Guest Post by Heather Haro. If youve been feeling the pressure of tighter margins and unpredictable inventory (hi, GLP-1s), Ive got good news: you can stop chasing unicorns and start stacking smart wins. Lets talk about four under-the-radar products that are easy to stock, simple to market, and wildly useful for your patients. Plus, Ill introduce you to a vendor that can make this transition seamless and profitable FH2 Pharma.

Patient Care 52

Patient Care Packaging Independent Pharmacies Dosage 52

Pharmacy Times

JUNE 3, 2025

Ralph Riello, PharmD, BCPS, a board-certified clinical pharmacy specialist at the Yale University School of Medicine, discusses challenges in implementation for novel cardiovascular treatments and interventions.

65

65

European Pharmaceutical Review

JUNE 3, 2025

As an essential aspect of quality control and ensuring the safety of pharmaceuticals, environmental monitoring is facing significant change. Professionals in the sector must adapt to overcome the major challenges impacting the industry, such as technological innovations, regulatory pressures, compliance and manufacturing complexities. Inside this report: Explore how leaders and innovators are navigating complex issues in the industry, including: Major trends shaping the pharmaceutical environmen

52

52

Pharmacy Times

JUNE 3, 2025

Electronic prior authorization (EPA) technology can streamline the complex process of obtaining prior authorizations for GLP-1 medications.

107

107

Fierce Healthcare

JUNE 3, 2025

A new class action lawsuit asserts the Department of Health and Human Services (HHS) and the Department of Government Efficiency (DOGE) fired civil servants based on incorrect internal personnel records.

94

94

Pharmacy Times

JUNE 3, 2025

Zongertinib shows promising efficacy and safety for HER2-mutant NSCLC, with a 71% response rate and low toxicity, paving the way for future treatments.

65

65

Pharma Marketing Network

JUNE 3, 2025

In todays crowded digital landscape, pharmaceutical brands face an increasingly complex task: turning awareness into action. While visibility remains important, engagement and conversion are what drive outcomes. That’s where CTAs (calls to action) come into play. For pharma marketers navigating strict compliance standards and shifting patient behavior, CTAs are not just marketing toolsthey are essential strategic assets.

Dosage 59

Dosage FDA Communication 59

pharmaphorum

JUNE 3, 2025

AstraZeneca and Daiichi Sankyo have revealed the data they hope will move Enhertu into frontline therapy for HER2-positive advanced breast cancer.

66

66

Fierce Healthcare

JUNE 3, 2025

Hospital-owned physician practices continue to grow as doctors steadily move away from private practice, citing significant financial and regulatory challenges that make it difficult to stay independent.

Hospitals 58

Hospitals 58

Pharmacy Times

JUNE 3, 2025

Clarity Breast's FDA-approved AI platform revolutionizes breast cancer risk prediction, enhancing early detection and personalized prevention strategies.

FDA 65

FDA 65

European Pharmaceutical Review

JUNE 3, 2025

BioNTech SEandBristol Myers Squibb ( BMS )have agreed a collaboration to advance a bispecific antibody, setting the stage for a potential new standard of care in cancer. BMS will pay BioNTech $1.5 billion upfront and $2 billion total in non-contingent anniversary payments through 2028. As part of the deal, BioNTech is also eligible for up to $7.6 billion in additional milestones.

52

52